Rapamune 1 mg 100 pcs. (Sirolimus/Rapamycin)

Rapamune® is indicated for the prevention of graft rejection in adult patients at low or moderate immunological risk after kidney transplantation. It is recommended to use Rapamune® initially in combination with glucocorticosteroids and cyclosporine microemulsion during the first 2-3 months after transplantation. Therapy with Rapamune® can be continued as maintenance therapy in conjunction with glucocorticosteroids only if cyclosporine is gradually discontinued.
Rapamune® is indicated for the treatment of patients with lymphangioleiomyomatosis.

Instructions

Composition

Contraindications

Special instructions

Side effects

Drug interactions